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Process Development for a 
Peptide Conjugated Qbeta Virus 
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Outline
• Background
• Confidence in Platform
– Robustness of process
– Process consistency
• Key Quality Attribute
– Peptide density vs. immunogenicity
• Manufacturing
– Drug substance process
– Process consistency with scaling
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What is Qβ VLP?
• Subunit is the capsid protein 
from Qβ bacteriophage
• 180 identical subunits self-
assemble to form the Virus-
Like Particle
• Proteins and nucleic acids 
from E. coli host cell are 
trapped in VLP
– RNA is necessary for proper 
VLP assembly
PNAS November 2, 2004 vol. 101 no. 44 15556-15560
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Qβ Background
•Technology licensed from Cytos Biotechnology AG in Schlieren Switzerland
Host Cell RNA
E.Coli RNA is packaged during assembly 




5 external conjugation 
sites per monomer
2 primary sites 
identified
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Qbeta Forms Consistently Shaped VLP
Particles
6
Electron microscopy image  
of purified Qbeta VLP
particles
Avg. diameter = 23+/-3 nm
Single VLP
Particle
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VLP Internal HCP’s are Consistent
• Up to 2% of the total protein present in VLP batches is HCP, of which 
98% is contained inside the VLP
• Capsid structure is disrupted to release internal HCP’s
• Western blot probed with anti-HCP antibodies shows a consistent 
banding pattern across different lots of VLP
Ref. Std.     Lot 1       Lot 2      Lot 3       Lot 4
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Probe set number (sorted by Pfizer lot avg intensity)






































































with free amines to form 
stable amide bond
Maleimide reacts 
with free sulfhydryl to form 
thioether bond
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Peptide Density is 
calculated from the 
monomer bands
Higher MW bands 
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Mechanisms of Cross-linking
• Cross-linking is mostly intra-VLP
– SEC data shows < 5% HMWS
• Mostly likely occurs before peptide addition
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0.5 ml Reactions 
PD 1.8 (500 mg)
PD - 2.9 (500 mg)
PD 1.7 (2.4g)
PD - 2.8 (1.4g)
Peptide 2
Peptide 1
For a given peptide density, SMPH
ratio can be predicted from curve
Peptide density is robust with 
increasing scale
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Small-scale Reactions Help Determine 
Manufacturing Conditions


















4 Hour Activation at RT

















Time and Temp Interaction
(10x SMPH)15ºC Activation
Systematic parameter optimization leads to the same conclusion as DoE
Increase activation time by 1 hour to adjust for lower temp at pilot plant   
in order to hit peptide density target
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Peptide density decreases with increasing pH 
Peptide density increases with increasing molar excess of SMPH
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3 + adjuvant 0.62
4 1.25
4 + adjuvant 1.25
5 1.56
5 + adjuvant 1.56
6 2.79
6 + adjuvant 2.79
Best responses with peptide density > 0.33
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Drug Substance Manufacturing Process
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Step 1 VLP and bifunctional linker, SMPH, mixed to form activated VLP
Step 2 Excess linker is removed by a DF operation 
Step 3 Peptide is added to the activated VLP
Step 4 Excess peptide is removed by a UF/DF operation
Step 5 Addition of excipients
Step 6 Final filter and packaging
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Conjugation Reaction is Consistent
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Lot Number 1 2 3 4 5 6
pH 7.3 7.2 7.2 7.2 7.2 7.2
Peptide Density peptides / monomer 2.5 2.5 2.5 2.4 2.4 2.5
Purity % purity 99.2 99.2 99.2 99.4 99.4 99.4
RNA Size average NT length 802 790 787 823 836 824
RNA Quantity μg/mg 233.5 Not Tested 238.7 258.4 261 253.5
Analytical Results for 6 Conjugates (100 mg lab scale)









Antibody titers are consistent among runs
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Process Consistency Immunogenicity 
Data
• Mice were 
vaccinated with 
samples from the 
6 consistency 
runs
• Antibody titers to 
the target antigen 
were measured
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is consistent as 
process is scaled
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Conclusions
• Conjugation to Qbeta VLP is a robust and 
reproducible platform for vaccine 
production.
• The process is robust from lab-scale to 
clinical manufacturing scale.
• Key quality attributes of peptide density 
and SEC purity are tightly controlled and 
are reproducible in terms of both lot 
consistency and batch scale.
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